SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark A. Stang who wrote (12413)8/1/1998 9:24:00 AM
From: betty moyers  Read Replies (1) of 23519
 
Mark, It is common to bring an investment banker in if you are
shopping around to sell the company. It is a wise thing to do in order to get full value.

If they made an announcement that they have employed an investment banker to explore all options of increasing shareholder value, it would be a boost to the stock.

Alternatively to selling the company,They could be looking at a revolving credit line for cash flow purposes. Since they have a clean balance sheet and are producing product with sales, this would be no problem.

I do not believe under the current circumstances, i.e. deflated stock price that they would consider a secondary offering. There is simply no reason for it. As stated above cash flow needs could easily and far more cheaply (in this environment) be done on a loan basis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News